Eric D. Braunstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric D. Braunstein has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Michael Shehata
Smidt Heart Institute, Cedars-Sinai, Los Angeles, California
4 shared publicationsXunzhang Wang
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
4 shared publicationsArchana Ramireddy
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
3 shared publicationsAshkan Ehdaie
Smidt Heart Institute, Cedars-Sinai, Los Angeles, California
3 shared publications- Luigi Di Biase
Montefiore Einstein Center for Heart and Vascular Care, Montefiore Medical Center , Bronx, NY, 10467
3 shared publications - Olga Reynbakh
Department of Medicine Division of Cardiology, Albert Einstein College of Medicine/Montefiore Medical Center Bronx New York USA
2 shared publications
Latest Publications
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (6) , e014442
Utilization and Outcomes of Permanent Pacemakers After Bicaval Heart Transplantation: A Large Institutional Experience
BACKGROUND: Permanent pacemaker (PPM) implantation after heart transplantation (HT) is common, but contemporary data regarding utilization, outcomes, and emerging pacing technologies are limited. METHODS: We studied PPM placement among 1225 bicaval HT recipients (28% women) treated at our institution from 2010 to 2025 and compared PPM recipients with HT patients without PPMs matched on sex, age, and transplant year. RESULTS: Median age at HT was 58 years (interquartile range, 48–65 years). Sixty-six (5%) patients received a PPM, with stable implantation rates over time. Median HT-to-PPM time was 4.3 months (interquartile range, 2 weeks to 4.8 years). The main indications were sinus node dysfunction (41 patients, 62%) or atrioventricular block (19 patients, 29%). Median post-HT survival was similar between PPM and non-PPM recipients (12.8 versus 11.5 years, P =0.14). Older organ donor age independently predicted PPM placement (odds ratio, 1.75; P =0.04). After 3.2 years of median follow-up, 1 transvenous PPM had a major complication requiring device extraction. Thirteen (20%) patients received leadless PPMs, including 3 atrial leadless PPMs and 1 dual-chamber leadless PPM. Leadless PPMs had no short-term complications over 1 year of median follow-up. CONCLUSIONS: Post-HT PPM implantation rates were low and unchanged since 2010. Most devices were implanted for sinus node dysfunction, with 44% implanted within 1 month post-HT. PPM placement was not associated with post-HT survival. Advanced organ donor age was associated with risk of PPM placement. Transvenous PPM complication rates were comparable to rates described in general populations. Leadless PPMs accounted for a substantial minority of PPM placements since their introduction in 2018, with no complications to date. Longer follow-up is needed to establish their long-term outcomes and safety in patients with HT.
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (6) , e014442
Utilization and Outcomes of Permanent Pacemakers After Bicaval Heart Transplantation: A Large Institutional Experience
BACKGROUND: Permanent pacemaker (PPM) implantation after heart transplantation (HT) is common, but contemporary data regarding utilization, outcomes, and emerging pacing technologies are limited. METHODS: We studied PPM placement among 1225 bicaval HT recipients (28% women) treated at our institution from 2010 to 2025 and compared PPM recipients with HT patients without PPMs matched on sex, age, and transplant year. RESULTS: Median age at HT was 58 years (interquartile range, 48–65 years). Sixty-six (5%) patients received a PPM, with stable implantation rates over time. Median HT-to-PPM time was 4.3 months (interquartile range, 2 weeks to 4.8 years). The main indications were sinus node dysfunction (41 patients, 62%) or atrioventricular block (19 patients, 29%). Median post-HT survival was similar between PPM and non-PPM recipients (12.8 versus 11.5 years, P =0.14). Older organ donor age independently predicted PPM placement (odds ratio, 1.75; P =0.04). After 3.2 years of median follow-up, 1 transvenous PPM had a major complication requiring device extraction. Thirteen (20%) patients received leadless PPMs, including 3 atrial leadless PPMs and 1 dual-chamber leadless PPM. Leadless PPMs had no short-term complications over 1 year of median follow-up. CONCLUSIONS: Post-HT PPM implantation rates were low and unchanged since 2010. Most devices were implanted for sinus node dysfunction, with 44% implanted within 1 month post-HT. PPM placement was not associated with post-HT survival. Advanced organ donor age was associated with risk of PPM placement. Transvenous PPM complication rates were comparable to rates described in general populations. Leadless PPMs accounted for a substantial minority of PPM placements since their introduction in 2018, with no complications to date. Longer follow-up is needed to establish their long-term outcomes and safety in patients with HT.
- 5 August 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (12) , e1269-e1274
Cardiac implantable electronic device implantation and function after transcatheter tricuspid valve replacement
- 5 August 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (12) , e1269-e1274
Cardiac implantable electronic device implantation and function after transcatheter tricuspid valve replacement
- 18 July 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (11) , 2999-3001
ICD electrical reset message owing to a programmer decoding error—A rare cause of no concern
- 18 July 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (11) , 2999-3001
ICD electrical reset message owing to a programmer decoding error—A rare cause of no concern
- Open Access
- 19 January 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 6 (4) , 402-409
Insights from the use of multipolar mapping during ablation of supraventricular and ventricular arrhythmias
- 19 January 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 6 (4) , 402-409
Open AccessInsights from the use of multipolar mapping during ablation of supraventricular and ventricular arrhythmias
- 10 March 2023
- Published by S. Karger AG in Cardiology
- Vol. 148 (2) , 131-133
Antiarrhythmic Drug Therapy for Ventricular Arrhythmias: The Changing Role in the Modern Era
Antiarrhythmic drugs (AADs) are powerful tools for suppression of ventricular arrhythmias (VAs). In the modern era, the role of AADs has evolved from the primary method of prevention of sudden cardiac death to an important element of multimodality treatment of VAs that can include medications, cardiac implantable electronic devices, and catheter-based ablation procedures. In this editorial, we discuss the changing role of AADs, and how they fit into the quickly evolving arena of intervention available for VAs.
- 10 March 2023
- Published by S. Karger AG in Cardiology
- Vol. 148 (2) , 131-133
Antiarrhythmic Drug Therapy for Ventricular Arrhythmias: The Changing Role in the Modern Era
Antiarrhythmic drugs (AADs) are powerful tools for suppression of ventricular arrhythmias (VAs). In the modern era, the role of AADs has evolved from the primary method of prevention of sudden cardiac death to an important element of multimodality treatment of VAs that can include medications, cardiac implantable electronic devices, and catheter-based ablation procedures. In this editorial, we discuss the changing role of AADs, and how they fit into the quickly evolving arena of intervention available for VAs.
- 30 December 2022
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (3) , 710-717
Initial experience with stylet‐driven versus lumenless lead delivery systems for left bundle branch area pacing
Introduction: Left bundle branch area pacing (LBBP) has emerged as an alternative method for conduction system pacing. While initial experience with delivery systems for stylet‐driven and lumenless lead implantation for LBBP has been described, data comparing outcomes of stylet‐driven versus lumenless lead implantation for LBBP are limited. In this study, we compare success rates and outcomes of LBBP with stylet‐driven versus lumenless lead delivery systems.Methods: Eighty‐three consecutive patients (mean age 74.1 ± 11.2 years; 56 [68%] male) undergoing attempted LBBP at a single institution were identified. Cases were grouped by lead delivery systems used: stylet‐driven (n = 53) or lumenless (n = 30). Baseline characteristics and procedural findings were recorded and compared between the cohorts. Intermediate term follow‐up data on ventricular lead parameters were also compared.Results: Baseline characteristics were similar between groups. Successful LBBP was achieved in 77% of patients, with similar success rates between groups (76% in stylet‐driven, 80% in lumenless, p = 0.79), and rates of adjudicated LBB capture and other paced QRS parameters were also similar. Compared with the lumenless group, the stylet‐driven group had significantly shorter procedure times (90 ± 4 vs. 112 ± 31 min, p = 0.004) and fluoroscopy times (10 ± 5 vs. 15 ± 6 min, p = 0.003). Ventricular lead parameters at follow‐up were similar, and rates of procedural complications and need for lead revision were low in both groups.Conclusion: Delivery systems for stylet‐driven and for lumenless leads for LBBP have comparable acute success rates. Long‐term follow‐up of lead performance following use of the various delivery systems is warranted.
- 30 December 2022
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (3) , 710-717
Initial experience with stylet‐driven versus lumenless lead delivery systems for left bundle branch area pacing
Introduction: Left bundle branch area pacing (LBBP) has emerged as an alternative method for conduction system pacing. While initial experience with delivery systems for stylet‐driven and lumenless lead implantation for LBBP has been described, data comparing outcomes of stylet‐driven versus lumenless lead implantation for LBBP are limited. In this study, we compare success rates and outcomes of LBBP with stylet‐driven versus lumenless lead delivery systems.Methods: Eighty‐three consecutive patients (mean age 74.1 ± 11.2 years; 56 [68%] male) undergoing attempted LBBP at a single institution were identified. Cases were grouped by lead delivery systems used: stylet‐driven (n = 53) or lumenless (n = 30). Baseline characteristics and procedural findings were recorded and compared between the cohorts. Intermediate term follow‐up data on ventricular lead parameters were also compared.Results: Baseline characteristics were similar between groups. Successful LBBP was achieved in 77% of patients, with similar success rates between groups (76% in stylet‐driven, 80% in lumenless, p = 0.79), and rates of adjudicated LBB capture and other paced QRS parameters were also similar. Compared with the lumenless group, the stylet‐driven group had significantly shorter procedure times (90 ± 4 vs. 112 ± 31 min, p = 0.004) and fluoroscopy times (10 ± 5 vs. 15 ± 6 min, p = 0.003). Ventricular lead parameters at follow‐up were similar, and rates of procedural complications and need for lead revision were low in both groups.Conclusion: Delivery systems for stylet‐driven and for lumenless leads for LBBP have comparable acute success rates. Long‐term follow‐up of lead performance following use of the various delivery systems is warranted.
- 21 December 2022
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (2) , 327-334
Ablation of atrial fibrillation beyond pulmonary vein isolation: Do additional ablation lesions impact left atrial function?
Introduction: Electrical isolation of pulmonary veins (PVI) is a cornerstone for atrial fibrillation (AF) ablation. The overall effect of AF ablation, and especially lesions beyond PVI, on left atrial (LA) function is currently poorly understood. Our aim was to determine if LA function is different in patients after extensive LA ablation compared to PVI only. We performed non‐inferiority analysis of LA function after PVI with additional nonpulmonary vein ablation lesions in LA (PVI+) and PVI alone.Methods: We studied 68 patients consecutive patients who underwent AF ablation and who had complete transthoracic echocardiogram (TTE) within 12 months before AF ablation and 1−12 months after the procedure. Patients were stratified into two groups: PVI only and PVI+. Primary outcome was change in LA reservoir strain (LASr). Noninferiority margin was defined at 6%.Results: The PVI only group had a higher proportion of patients with paroxysmal AF (70% vs. 30%). The PVI+ group was observed to have a slightly higher increase in LASr compared to PVI alone (5.0% vs. 4.3%, p < .01 for noninferiority). LASr noninferiority was confirmed when adjusted for age, sex, coronary artery disease, hyperlipidemia, and AF type, rhythm at preprocedure TTE in a multivariable linear regression model, 90% CI (−5.46 to 2.04), p < .01.Conclusion: LA functional improvement evaluated by LASr was noninferior after PVI with additional LA ablation lesions compared to PVI alone. These findings were confirmed when adjusted for confounding clinical variables, suggesting that more extensive ablation does not negatively affect LA function.
- 21 December 2022
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (2) , 327-334
Ablation of atrial fibrillation beyond pulmonary vein isolation: Do additional ablation lesions impact left atrial function?
Introduction: Electrical isolation of pulmonary veins (PVI) is a cornerstone for atrial fibrillation (AF) ablation. The overall effect of AF ablation, and especially lesions beyond PVI, on left atrial (LA) function is currently poorly understood. Our aim was to determine if LA function is different in patients after extensive LA ablation compared to PVI only. We performed non‐inferiority analysis of LA function after PVI with additional nonpulmonary vein ablation lesions in LA (PVI+) and PVI alone.Methods: We studied 68 patients consecutive patients who underwent AF ablation and who had complete transthoracic echocardiogram (TTE) within 12 months before AF ablation and 1−12 months after the procedure. Patients were stratified into two groups: PVI only and PVI+. Primary outcome was change in LA reservoir strain (LASr). Noninferiority margin was defined at 6%.Results: The PVI only group had a higher proportion of patients with paroxysmal AF (70% vs. 30%). The PVI+ group was observed to have a slightly higher increase in LASr compared to PVI alone (5.0% vs. 4.3%, p < .01 for noninferiority). LASr noninferiority was confirmed when adjusted for age, sex, coronary artery disease, hyperlipidemia, and AF type, rhythm at preprocedure TTE in a multivariable linear regression model, 90% CI (−5.46 to 2.04), p < .01.Conclusion: LA functional improvement evaluated by LASr was noninferior after PVI with additional LA ablation lesions compared to PVI alone. These findings were confirmed when adjusted for confounding clinical variables, suggesting that more extensive ablation does not negatively affect LA function.
- Open Access
- 25 November 2022
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 9 (2) , 105-108
Catheter ablation of typical and atypical atrial flutters in a patient with transcatheter tricuspid valve replacement
- 25 November 2022
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 9 (2) , 105-108
Open AccessCatheter ablation of typical and atypical atrial flutters in a patient with transcatheter tricuspid valve replacement
- Open Access
- 14 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Arrhythmia patterns in patients with COVID-19 infection during and post hospitalization detected via a patch-based mobile cardiac telemetry system
Background: Coronavirus infection (COVID-19) is the cause of the current world-wide pandemic. Cardiovascular complications occur in 20–30% of patients with COVID-19 infection including myocardial injury and arrhythmias. Current understanding of specific arrhythmia type and frequency is limited. In response to COVID-19 pandemic and overwhelmed hospital critical care and telemetry recourses, patch-based cardiac monitoring system received emergency Food and Drug Administration (FDA) approval for inpatient monitoring. A patch-based cardiac telemetry system has been shown to be useful for patient management during the COVID-19 pandemic and provides detailed analysis of cardiac rhythms. Purpose: To analyze arrhythmia type and frequency in patients with COVID-19 infection, identifying arrhythmia patterns over time during hospitalization and after discharge. Methods: A prospective cohort study during the COVID-19 pandemic was performed. We included patients hospitalized with COVID-19 infection who had a patch-based mobile telemetry device placed for cardiac monitoring. A quantitative analysis including type, frequency and duration of detected arrhythmias was performed at the end of the monitoring period. Results: A total of 103 patients hospitalized with COVID-19 diagnosis underwent monitoring. Quantitative reports for 59 patients were available for analysis, among those 59% were males, median age 65 (IQR 56–76) yrs. Mean wear time was 6.8±5.0 days. Arrhythmias were detected in 72.9% of patients. Majority of arrhythmias were SVT (59.3% of patients) and AF (22.0%). Episodes of AF duration >30 min were detected in 12 patients. New onset AF was noted in 15.0% of patients and was significantly associated with age (OR 1.4 for 5 yrs difference; 95% CI 1.01–2.05). Brady arrhythmias (2nd degree, 3rd degree AV bock, pause≥3 seconds) were seen in 18.7% of patients. Arrhythmias were consistently detected throughout the monitoring period in 52.9%-89.5% of patients daily (Figure 1). In 9 patients who were discharged with continued patch monitoring, 3 patients (33.3%) had arrhythmic events during their outpatient monitoring period. Conclusion: A majority of patients hospitalized with COVID-19 infection had arrhythmias detected by patch cardiac monitor. Arrhythmias were observed throughout hospitalization with a consistent daily frequency. Patients continued to exhibit cardiac arrhythmias after hospital discharge of a type similar to that seen during hospitalization. New onset AF often occurred and was associated with older age. Inpatient application of a patch cardiac telemetry with continued monitoring as outpatient is feasible and effective in detecting occult arrhythmias in patients with COVID-19 infection. Funding Acknowledgement: Type of funding sources: None. Daily frequency of arrhythmias detected
- 14 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Open AccessArrhythmia patterns in patients with COVID-19 infection during and post hospitalization detected via a patch-based mobile cardiac telemetry system
Background: Coronavirus infection (COVID-19) is the cause of the current world-wide pandemic. Cardiovascular complications occur in 20–30% of patients with COVID-19 infection including myocardial injury and arrhythmias. Current understanding of specific arrhythmia type and frequency is limited. In response to COVID-19 pandemic and overwhelmed hospital critical care and telemetry recourses, patch-based cardiac monitoring system received emergency Food and Drug Administration (FDA) approval for inpatient monitoring. A patch-based cardiac telemetry system has been shown to be useful for patient management during the COVID-19 pandemic and provides detailed analysis of cardiac rhythms. Purpose: To analyze arrhythmia type and frequency in patients with COVID-19 infection, identifying arrhythmia patterns over time during hospitalization and after discharge. Methods: A prospective cohort study during the COVID-19 pandemic was performed. We included patients hospitalized with COVID-19 infection who had a patch-based mobile telemetry device placed for cardiac monitoring. A quantitative analysis including type, frequency and duration of detected arrhythmias was performed at the end of the monitoring period. Results: A total of 103 patients hospitalized with COVID-19 diagnosis underwent monitoring. Quantitative reports for 59 patients were available for analysis, among those 59% were males, median age 65 (IQR 56–76) yrs. Mean wear time was 6.8±5.0 days. Arrhythmias were detected in 72.9% of patients. Majority of arrhythmias were SVT (59.3% of patients) and AF (22.0%). Episodes of AF duration >30 min were detected in 12 patients. New onset AF was noted in 15.0% of patients and was significantly associated with age (OR 1.4 for 5 yrs difference; 95% CI 1.01–2.05). Brady arrhythmias (2nd degree, 3rd degree AV bock, pause≥3 seconds) were seen in 18.7% of patients. Arrhythmias were consistently detected throughout the monitoring period in 52.9%-89.5% of patients daily (Figure 1). In 9 patients who were discharged with continued patch monitoring, 3 patients (33.3%) had arrhythmic events during their outpatient monitoring period. Conclusion: A majority of patients hospitalized with COVID-19 infection had arrhythmias detected by patch cardiac monitor. Arrhythmias were observed throughout hospitalization with a consistent daily frequency. Patients continued to exhibit cardiac arrhythmias after hospital discharge of a type similar to that seen during hospitalization. New onset AF often occurred and was associated with older age. Inpatient application of a patch cardiac telemetry with continued monitoring as outpatient is feasible and effective in detecting occult arrhythmias in patients with COVID-19 infection. Funding Acknowledgement: Type of funding sources: None. Daily frequency of arrhythmias detected
- Open Access
- 27 August 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (11) , 2803-2811
Inpatient cardiac monitoring using a patch‐based mobile cardiac telemetry system during the COVID‐19 pandemic
Introduction: Coronavirus disease 2019 (COVID‐19) is a worldwide pandemic, and cardiovascular complications and arrhythmias in these patients are common. Cardiac monitoring is recommended for at risk patients; however, the availability of telemetry capable hospital beds is limited. We sought to evaluate a patch‐based mobile telemetry system for inpatient cardiac monitoring during the pandemic.Methods: A prospective cohort study was performed of inpatients hospitalized during the pandemic who had mobile telemetry devices placed; patients were studied up until the time of discharge or death. The primary outcome was a composite of management changes based on data obtained from the system and detection of new arrhythmias. Other clinical outcomes and performance characteristics of the mobile telemetry system were studied.Results: Eighty‐two patients underwent mobile telemetry device placement, of which 31 (37.8%) met the primary outcome, which consisted of 24 (29.3%) with new arrhythmias detected and 18 (22.2%) with management changes. Twenty‐one patients (25.6%) died during the study, but none from primary arrhythmias. In analyses, age and heart failure were associated with the primary outcome. Monitoring occurred for an average of 5.3 ± 3.4 days, with 432 total patient‐days of monitoring performed; of these, QT‐interval measurements were feasible in 400 (92.6%).Conclusion: A mobile telemetry system was successfully implemented for inpatient use during the COVID‐19 pandemic and was shown to be useful to inform patient management, detect occult arrhythmias, and monitor the QT‐interval. Patients with advanced age and structural heart disease may be more likely to benefit from this system.
- 27 August 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (11) , 2803-2811
Open AccessInpatient cardiac monitoring using a patch‐based mobile cardiac telemetry system during the COVID‐19 pandemic
Introduction: Coronavirus disease 2019 (COVID‐19) is a worldwide pandemic, and cardiovascular complications and arrhythmias in these patients are common. Cardiac monitoring is recommended for at risk patients; however, the availability of telemetry capable hospital beds is limited. We sought to evaluate a patch‐based mobile telemetry system for inpatient cardiac monitoring during the pandemic.Methods: A prospective cohort study was performed of inpatients hospitalized during the pandemic who had mobile telemetry devices placed; patients were studied up until the time of discharge or death. The primary outcome was a composite of management changes based on data obtained from the system and detection of new arrhythmias. Other clinical outcomes and performance characteristics of the mobile telemetry system were studied.Results: Eighty‐two patients underwent mobile telemetry device placement, of which 31 (37.8%) met the primary outcome, which consisted of 24 (29.3%) with new arrhythmias detected and 18 (22.2%) with management changes. Twenty‐one patients (25.6%) died during the study, but none from primary arrhythmias. In analyses, age and heart failure were associated with the primary outcome. Monitoring occurred for an average of 5.3 ± 3.4 days, with 432 total patient‐days of monitoring performed; of these, QT‐interval measurements were feasible in 400 (92.6%).Conclusion: A mobile telemetry system was successfully implemented for inpatient use during the COVID‐19 pandemic and was shown to be useful to inform patient management, detect occult arrhythmias, and monitor the QT‐interval. Patients with advanced age and structural heart disease may be more likely to benefit from this system.